A Multicenter Phase I Clinical Trial of Ribavirin in the Treatment of Patients With AIDS and Advanced AIDS Related Illnesses

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-01

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses. Also, to determine what effect different dosage levels have on biologic markers of efficacy, such as the amount of the AIDS virus (HIV) or number of T cells in the patient's blood. RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).

CONDITIONS

Brief Title

A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Short-course therapy (7 days) with oral acyclovir.
Short-course therapy (7 days) with ketoconazole.
Topical medications.
Aerosolized pentamidine for prophylactic purposes.

Concurrent Treatment:

Allowed:

Blood transfusions for hemoglobin toxicity.

Patients must have two positive HIV p24 antigen tests with titers = or > 70 picograms at least 72 hours apart and within 1 month prior to entry, the last of which must be within 2 weeks of starting therapy.

Prior Medication:

Allowed:

Zidovudine (AZT), without cessation of therapy required due to intolerance.
AZT therapy must be discontinued at least 30 days prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.

Concurrent Medication:

Excluded:

Ongoing systemic therapy and/or prophylaxis for an AIDS-defining opportunistic infection.
Antineoplastic therapy.
Other experimental medications.
Systemic chemoprophylaxis for Pneumocystis carinii pneumonia.
Chronic (> 7 days) oral acyclovir therapy.

Concurrent Treatment:

Excluded:

Blood transfusions unless they are for = or > grade 3 hemoglobin toxicity.

Patients with the following are excluded:

Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.

Prior Medication:

Excluded within 30 days of study entry: